Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

Conditions

• Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Adaptive Radiation Therapy — RADIATION
  Adaptive Radiation Therapy (ART) creates a personalized radiation plan for each treatment session. This means the plan can change from day to day to more precisely target the tumor while protecting the surrounding healthy tissue. By closely shaping the radiation to match the tumor's location, ART may reduce the amount of radiation reaching nearby normal tissues. This can allow for higher, more focused doses of radiation to the tumor itself, which may help improve treatment effectiveness while reducing side effects.

Study Details

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer. The main questions the study aims to answer are: * Can ART improve how well radiation therapy targets the most aggressive cancer cells, while protecting the healthy tissue around the tumor? * Can ART help reduce the side effects that participants may experience during treatment? Participants will: * Undergo CT scans to plan the exact location of the radiation treatment. During this process, 1-3 small markers may be placed in or near the tumor to help with the planning. * Have a tumor biopsy, which involves taking a small sample of tissue from the cancer. * Receive 5 radiation treatments every other day over a 2-week period. * Provide blood samples before, during, and after your radiation treatment.

Key Dates

Start date

Aug 20, 2025

Status verified

Sep 2025

Primary completion

Aug 1, 2028

Completion

Aug 1, 2029

Study Design

Enrollment

16 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Single-Arm
  Adaptive Radiation Therapy

Primary Outcome Measure

The rate of acute and late grade ≥3 gastrointestinal toxicity occurring within 3 months of treatment possibly, probably or definitely related to radiation. [ Time Frame: From start of radiation to 3 months after the end of radiation treatment ]

Central Contacts

• Joshua Meyer, MD
  215-728-2667
  [email protected]
• Jianli Hu, MD, PhD
  267-449-1431
  [email protected]

Locations (1)

Find similar trials in Philadelphia, PA